Our 10-year and lifetime CVD risk calculators are not good enough and do not results in immediate preventive actions. We need a short-term predictor, preferably a 12-month forecast, and we can create it with existing cohorts, machine learning, and a pioneering IT company like Google, Apple, IBM,...
Houston, TX (PRWEB) September 19, 2017
For decades doctors, nurses, and other healthcare providers have been trained to assess an individual's risk of a heart attack by measuring their risk factors and calculating their cardiovascular disease (CVD) risk in the next 10 years.
Imagine if hurricanes Harvey and Irma were predicted the same way CVD is predicted today: an estimated 10-year risk prediction!
Imagine if the weatherman says there is a 7.5% chance of a category 5 hurricane in the next 10 years.
Do you think people would take immediate preventive actions like boarding up their windows, buying hurricane supplies, or even changing their daily routines???
Most likely not, because long term predictions do not trigger immediate preventive actions. This is why Cardiology needs a short-term predictor (preferably 6-12 month forecast), and we (SHAPE and collaborators) are going to create it.
Visit http://shapesociety.org/the-first-machine-learning-heart-attack-forecast-symposium to find out how we are using machine learning and existing cohorts to tackle this problem.
Join thousands of doctors, nurses, and other cardiovascular professionals at the upcoming 2017 scientific sessions of the American Heart Association and learn about SHAPE's initiative to develop a short-term CVD risk predictor.
Make sure to attend the SHAPE Symposium (Monday, November 13, 2017, 7-9PM), and also participate in the following AHA session where Dr. Morteza Naghavi, the founder of SHAPE and the leader of "Machine Learning Vulnerable Patient", presents the following breakthrough findings:
AHA 2017, November 13, 3:40 PM, Orange County Convention Center, Anaheim, California.
Monday, November 13, 2017, 3:40 pm
Machine Learning Outperformed ACC/AHA Pooled Cohort Equations Risk Calculator for Detection of High-Risk Asymptomatic Individuals and Recommending Treatment for Prevention of Cardiovascular Events in the Multi-Ethnic Study of Atherosclerosis (MESA)
Ioannis A. Kakadiaris, Ph.D.1, Michalis Vrigkas, Ph.D.1, Matthew Budoff, M.D.2, Albert A. Yen, M.D.3, Morteza Naghavi, M.D.4
Institutional Affiliations [1: Computational Biomedicine Lab, University of Houston, Houston, TX, USA; 2: Division of Cardiology, Los Angeles Biomedical Research at Harbor-UCLA Medical Center, Torrance, CA, USA; 3: MEDITEX (Medical Innovations in Texas), Houston, TX, USA; 4: Society for Heart Attack Prevention and Eradication, Houston, TX, USA]
Morteza Naghavi, M.D.
Society for Heart Attack Prevention and Eradication (SHAPE), Houston, TX 77024, USA
(+1) 877-SHAPE11 (877-742-7311)
The Society for Heart Attack Prevention and Eradication (SHAPE) is a non-profit organization that promotes education and research related to prevention, detection, and treatment of heart attacks. SHAPE is committed to raising public awareness about revolutionary discoveries that are opening exciting avenues to prevent heart attacks. SHAPE's mission is to eradicate heart attacks in the 21st century. Additional information is available on the organization's website at http://www.shapesociety.org or by calling 1-877-SHAPE11 or 713-529-4484.
About SHAPE Task Force:
The SHAPE Task Force, an international group of leading cardiovascular physicians and researchers, has created the SHAPE Guidelines, which educates physicians on how to identify asymptomatic atherosclerosis (hidden plaques) and implement proper therapies to prevent a future heart attack. According to the SHAPE Guidelines, men 45-75 and women 55-75 need to be tested for hidden plaques in coronary or carotid arteries. Individuals with high risk atherosclerosis (high plaque score) should be treated even if their cholesterol level is within statistical “normal range.” If they have plaques, the so-called normal is not normal for them. The higher the amount of plaque burden in the arteries the higher the risk and the more vulnerable to heart attack. SHAPE Guideline aims to identify the asymptomatic “Vulnerable Patient” and offer them intensive preventive therapy to prevent a future heart attack. Knowing one's plaque score can be a matter of life and death. Additional information is available by calling 1-877-SHAPE11 or 713-529-4484. And Additional information is available at http://www.shapesociety.org.
The SHAPE Task Force includes the following:
Morteza Naghavi, M.D. – Executive Chairman
PK Shah, M.D. – Chair of Scientific Board
Erling Falk, M.D., Ph.D. – Chief of Editorial Committee
SHAPE Task Force Members and Advisors (alphabetic order):
Arthur Agatston, M.D., Daniel Arking, Ph.D., Juan Badimon, Ph.D., Raymond Bahr, M.D., Daniel S. Berman, M.D., Matthew J. Budoff, M.D., Jay Cohn, M.D., Michael Davidson, M.D., Raimund Erbel, M.D., Erling Falk, M.D., Ph.D., Zahi Fayad, Ph.D., Sergio Fazio, MD, PhD, Steven B. Feinstein, M.D., Craig Hartley, Ph.D., Harvey S. Hecht, M.D., Howard Hodis, M.D., Ioannis Kakadiaris, Ph.D., Sanjay Kaul, M.D., M.P.H., Asher Kimchi. M.D., Wolfgang Koenig, M.D., Ph.D., Iftikhar J. Kullo, M.D., Daniel Lane, M.D., Ph.D., David Maron, M.D., Roxana Mehran, M.D., Ralph Metcalfe, Ph.D., Morteza Naghavi, M.D., Khurram Nasir, M.D., M.P.H., Tasneem Z. Naqvi, M.D., Jagat Narula, M.D., Paolo Raggi, M.D., George P. Rodgers, M.D., James HF Rudd, Ph.D., John A. Rumberger, PhD, M.D., Robert S. Schwartz, M.D., PK Shah, M.D., Leslee Shaw, Ph.D., David Spence, M.D., H. Robert Superko, M.D., Henrik Sillesen, M.D., Ph.D., Pierre-Jean Touboul, M.D. Nathan D. Wong, Ph.D.
Distinguished SHAPE Task Force Advisor: Valentin Fuster, M.D., Ph.D.
Chair of SHAPE Board of Directors: JoAnne Zawitoski, J.D.
Vice Chair and Executive Board Member: Brenda Garrett Superko, CVRN
SHAPE Task Force Public Relations: Daniel Keeney
For SHAPE Volunteer and Sponsorship Opportunities Please Contact email@example.com